Merck & Co Inc
MRK106.850USD
+0.400+0.38%
Handelsschluss 12/26, 16:00（ET）Kurse um 15 Minuten verzögert
265.77BMarktkapitalisierung
14.10KGV TTM
mehr Informationen über Merck & Co Inc Unternehmen
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
Merck & Co Inc Informationen
BörsenkürzelMRK
Name des UnternehmensMerck & Co Inc
IPO-datumFeb 06, 2077
CEODavis (Robert M)
Anzahl der mitarbeiter75000
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 06
Addresse126 East Lincoln Avenue
StadtRAHWAY
BörseNASDAQ OMX NASDAQ Basic NYSE
LandUnited States of America
Postleitzahl07065
Telefon19087404000
Websitehttps://www.merck.com/
BörsenkürzelMRK
IPO-datumFeb 06, 2077
CEODavis (Robert M)
Führungskräfte von Merck & Co Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Robert M. (Rob) Davis
Mr. Robert M. (Rob) Davis
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
443.60K
--
Mr. Sanat Chattopadhyay
Mr. Sanat Chattopadhyay
Executive Vice President and President - Merck Manufacturing Division
Executive Vice President and President - Merck Manufacturing Division
185.33K
+17.90%
Mr. Chirfi Guindo
Mr. Chirfi Guindo
Senior Vice President, Chief Marketing Officer - Human Health
Senior Vice President, Chief Marketing Officer - Human Health
85.34K
+28.11%
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Executive Vice President, President - Merck Research Laboratories
Executive Vice President, President - Merck Research Laboratories
79.59K
+0.92%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Executive Vice President, General Counsel
Executive Vice President, General Counsel
53.42K
+90.81%
Mr. Joseph Edward Romanelli
Mr. Joseph Edward Romanelli
Senior Vice President, President - MSD International Human Health
Senior Vice President, President - MSD International Human Health
22.91K
+5.27%
Ms. Patricia F. Russo
Ms. Patricia F. Russo
Independent Director
Independent Director
13.15K
--
Mr. Thomas Henry (Tom) Glocer, J.D.
Mr. Thomas Henry (Tom) Glocer, J.D.
Lead Independent Director
Lead Independent Director
5.10K
--
Mr. Inge G. Thulin
Mr. Inge G. Thulin
Independent Director
Independent Director
2.93K
--
Ms. Pamela J. Craig
Ms. Pamela J. Craig
Independent Director
Independent Director
1.72K
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Robert M. (Rob) Davis
Mr. Robert M. (Rob) Davis
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
443.60K
--
Mr. Sanat Chattopadhyay
Mr. Sanat Chattopadhyay
Executive Vice President and President - Merck Manufacturing Division
Executive Vice President and President - Merck Manufacturing Division
185.33K
+17.90%
Mr. Chirfi Guindo
Mr. Chirfi Guindo
Senior Vice President, Chief Marketing Officer - Human Health
Senior Vice President, Chief Marketing Officer - Human Health
85.34K
+28.11%
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Executive Vice President, President - Merck Research Laboratories
Executive Vice President, President - Merck Research Laboratories
79.59K
+0.92%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Executive Vice President, General Counsel
Executive Vice President, General Counsel
53.42K
+90.81%
Mr. Joseph Edward Romanelli
Mr. Joseph Edward Romanelli
Senior Vice President, President - MSD International Human Health
Senior Vice President, President - MSD International Human Health
22.91K
+5.27%
Umsatzaufteilung
Währung: USDAktualisiert: Mon, Oct 6
Währung: USDAktualisiert: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Oncology-Keytruda
7.96B
50.34%
Vaccines -Gardasil/Gardasil
1.13B
7.12%
Animal Health-Livestock
961.00M
6.08%
Animal Health-Companion Animals
685.00M
4.33%
Vaccines -ProQuad/M-M-R II/Varivax
609.00M
3.85%
Andere
4.47B
28.27%
Nach RegionUSD
Name
Umsatz
Anteil
United States
8.84B
55.90%
Europe, Middle East and Africa
3.66B
23.15%
Latin America
859.00M
5.43%
Asia Pacific (Other than China and Japan)
785.00M
4.97%
Japan
626.00M
3.96%
Andere
1.04B
6.59%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Oncology-Keytruda
7.96B
50.34%
Vaccines -Gardasil/Gardasil
1.13B
7.12%
Animal Health-Livestock
961.00M
6.08%
Animal Health-Companion Animals
685.00M
4.33%
Vaccines -ProQuad/M-M-R II/Varivax
609.00M
3.85%
Andere
4.47B
28.27%
Aktionärsstatistik
Aktualisiert: Mon, Nov 17
Aktualisiert: Mon, Nov 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
10.11%
BlackRock Institutional Trust Company, N.A.
5.69%
State Street Investment Management (US)
4.76%
Wellington Management Company, LLP
3.03%
Geode Capital Management, L.L.C.
2.41%
Andere
74.00%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
10.11%
BlackRock Institutional Trust Company, N.A.
5.69%
State Street Investment Management (US)
4.76%
Wellington Management Company, LLP
3.03%
Geode Capital Management, L.L.C.
2.41%
Andere
74.00%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
42.31%
Investment Advisor/Hedge Fund
26.78%
Research Firm
3.18%
Pension Fund
2.51%
Bank and Trust
2.21%
Sovereign Wealth Fund
1.55%
Hedge Fund
1.06%
Insurance Company
0.69%
Family Office
0.13%
Andere
19.59%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
5358
2.02B
81.35%
-45.75M
2025Q2
5398
2.02B
80.82%
-16.42M
2025Q1
5446
2.05B
81.47%
-3.32M
2024Q4
5410
2.04B
80.88%
+11.87M
2024Q3
5200
2.01B
79.47%
-7.96M
2024Q2
5181
2.01B
79.28%
-4.86M
2024Q1
5154
2.00B
78.88%
-6.10M
2023Q4
5065
1.99B
78.60%
+584.81K
2023Q3
4871
1.98B
78.17%
-32.03M
2023Q2
4864
2.00B
78.94%
-18.54M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
251.75M
10.08%
+356.59K
+0.14%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
142.78M
5.72%
-4.51M
-3.06%
Jun 30, 2025
State Street Investment Management (US)
118.49M
4.74%
-2.04M
-1.69%
Jun 30, 2025
Wellington Management Company, LLP
76.86M
3.08%
-4.81M
-5.89%
Jun 30, 2025
Geode Capital Management, L.L.C.
58.95M
2.36%
-704.59K
-1.18%
Jun 30, 2025
Charles Schwab Investment Management, Inc.
53.87M
2.16%
+4.64M
+9.42%
Jun 30, 2025
Norges Bank Investment Management (NBIM)
36.11M
1.45%
+1.13M
+3.23%
Jun 30, 2025
Fidelity Management & Research Company LLC
28.48M
1.14%
+229.47K
+0.81%
Jun 30, 2025
Fisher Investments
25.01M
1%
+567.90K
+2.32%
Jun 30, 2025
BlackRock Asset Management Ireland Limited
22.79M
0.91%
+764.14K
+3.47%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
VanEck Pharmaceutical ETF
16.09%
FT Vest DJIA Dogs 10 Target Income ETF
10.79%
First Trust NASDAQ Pharmaceuticals ETF
7.94%
Invesco Dow Jones Industrial Average Dividend ETF
6.94%
First Trust Morningstar Dividend Leaders Index Fund
5.39%
Coastal Compass 100 ETF
5.13%
Invesco Pharmaceuticals ETF
4.96%
VanEck Morningstar Wide Moat Value ETF
4.73%
Vaneck Durable High Dividend ETF
4.65%
Franklin Income Focus ETF
4.56%
Mehr Anzeigen
VanEck Pharmaceutical ETF
Anteil16.09%
FT Vest DJIA Dogs 10 Target Income ETF
Anteil10.79%
First Trust NASDAQ Pharmaceuticals ETF
Anteil7.94%
Invesco Dow Jones Industrial Average Dividend ETF
Anteil6.94%
First Trust Morningstar Dividend Leaders Index Fund
Anteil5.39%
Coastal Compass 100 ETF
Anteil5.13%
Invesco Pharmaceuticals ETF
Anteil4.96%
VanEck Morningstar Wide Moat Value ETF
Anteil4.73%
Vaneck Durable High Dividend ETF
Anteil4.65%
Franklin Income Focus ETF
Anteil4.56%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
35.12B
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Nov 18, 2025
MRK.NB Interim Cash Dividend of gross USD 0.85 paid on Jan 08, 2026 going ex on Dec 15, 2025
Dec 15, 2025
Jan 08, 2026
Dec 15, 2025
Jul 22, 2025
MRK.NB Final Cash Dividend of gross USD 0.81 paid on Oct 07, 2025 going ex on Sep 15, 2025
Sep 15, 2025
Oct 07, 2025
Sep 15, 2025
May 27, 2025
MRK.NB Interim Cash Dividend of gross USD 0.81 paid on Jul 08, 2025 going ex on Jun 16, 2025
Jun 16, 2025
Jul 08, 2025
Jun 16, 2025
Jan 28, 2025
MRK.NB Interim Cash Dividend of gross USD 0.81 paid on Apr 07, 2025 going ex on Mar 17, 2025
Mar 17, 2025
Apr 07, 2025
Mar 17, 2025
Nov 19, 2024
MRK.NB Final Cash Dividend of gross USD 0.81 paid on Jan 08, 2025 going ex on Dec 16, 2024
Dec 16, 2024
Jan 08, 2025
Dec 16, 2024
Jul 23, 2024
MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Oct 07, 2024 going ex on Sep 16, 2024
Sep 16, 2024
Oct 07, 2024
Sep 16, 2024
May 29, 2024
MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Jul 08, 2024 going ex on Jun 17, 2024
Jun 17, 2024
Jul 08, 2024
Jun 17, 2024
Jan 23, 2024
MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Apr 05, 2024 going ex on Mar 14, 2024
Mar 15, 2024
Apr 05, 2024
Mar 14, 2024
Nov 28, 2023
MRK.NB Final Cash Dividend of gross USD 0.77 paid on Jan 08, 2024 going ex on Dec 14, 2023
Dec 15, 2023
Jan 08, 2024
Dec 14, 2023
Jul 25, 2023
MRK.NB Interim Cash Dividend of gross USD 0.73 paid on Oct 06, 2023 going ex on Sep 14, 2023
Sep 15, 2023
Oct 06, 2023
Sep 14, 2023
Mehr Anzeigen
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Merck & Co Inc?
Die fünf größten Anteilseigner von Merck & Co Inc sind:
The Vanguard Group, Inc. hält 251.75M Aktien, was 10.08% der Gesamtaktien entspricht.
BlackRock Institutional Trust Company, N.A. hält 142.78M Aktien, was 5.72% der Gesamtaktien entspricht.
State Street Investment Management (US) hält 118.49M Aktien, was 4.74% der Gesamtaktien entspricht.
Wellington Management Company, LLP hält 76.86M Aktien, was 3.08% der Gesamtaktien entspricht.
Geode Capital Management, L.L.C. hält 58.95M Aktien, was 2.36% der Gesamtaktien entspricht.
The Vanguard Group, Inc. hält 251.75M Aktien, was 10.08% der Gesamtaktien entspricht.
BlackRock Institutional Trust Company, N.A. hält 142.78M Aktien, was 5.72% der Gesamtaktien entspricht.
State Street Investment Management (US) hält 118.49M Aktien, was 4.74% der Gesamtaktien entspricht.
Wellington Management Company, LLP hält 76.86M Aktien, was 3.08% der Gesamtaktien entspricht.
Geode Capital Management, L.L.C. hält 58.95M Aktien, was 2.36% der Gesamtaktien entspricht.
Was sind die drei wichtigsten Anteilseigner-Typen von Merck & Co Inc?
Die drei wichtigsten Anteilseigner-Typen von Merck & Co Inc sind:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
Wie viele Institutionen halten Anteile an Merck & Co Inc (MRK)?
Mit Stand vom 2025Q3 halten 5358 Institutionen Anteile an Merck & Co Inc, mit einem Gesamtmarktwert von etwa 2.02B, was 81.35% der Gesamtanteile entspricht. Im Vergleich zum 2025Q2 ist der institutionelle Aktienbesitz um 0.53% gestiegen.
Was ist die größte Einnahmequelle von Merck & Co Inc?
Am FY2025Q2 erzielte das Geschäft mit Oncology-Keytruda für Merck & Co Inc den höchsten Umsatz in Höhe von 7.96B, was 50.34% des Gesamtumsatzes entspricht.
